You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia
  1. Mathias Daheim,
  2. Sonja Lang,
  3. Tobias Goeser,
  4. Hans-Michael Steffen,
  5. Münevver Demir
  1. Clinic for Gastroenterology and Hepatology, University Hospital of Cologne, Cologne, Germany
  1. Correspondence to Dr Mathias Daheim, Clinic for Gastroenterology and Hepatology, University Hospital of Cologne, Germany; Kerpener Str. 62, Koeln D-50924, Germany; mathias.daheim{at}uk-koeln.de

https://doi.org/10.1136/gutjnl-2016-312993

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    With great interest we have read the recent paper by Poh et al 1 suggesting the use of a routine parameter-based risk score for the development of hepatocellular carcinoma (HCC) in Asian patients with chronic HBV infection (CHBV).

    With an estimated 240 million people being chronically infected by HBV worldwide, CHBV is a major global health burden, putting these people at risk for the development of liver cirrhosis and HCC.2–4

    It remains challenging to identify those patients with CHBV carrying a high risk for HCC development applying an easy to use, readily available and cost effective test system. Therefore risk predicting …

    View Full Text

    Footnotes

    • Contributors All authors contributed substantive to the manuscript by participating in the collection and assembly of data, data analysis and interpretation as well as writing the manuscript. Each author was involved in the final approval of the manuscript.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.